Phase I/II Thymus Transplantation With Immunosuppression #950
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously
described as transplantation) with tailored immunosuppression based on the recipient's
pre-implantation T cell population is a safe and effective treatment for complete DiGeorge
anomaly. This study will also evaluate whether cultured thymus tissue implantation and
parathyroid transplantation with immunosuppression is a safe and effective treatment for
complete DiGeorge anomaly and hypoparathyroidism.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M. Louise Markert
Collaborators:
Enzyvant Therapeutics GmbH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)